Premium
(−)‐Epigallocatechin gallate inhibits lipopolysaccharide‐induced microglial activation and protects against inflammation‐mediated dopaminergic neuronal injury
Author(s) -
Li Rui,
Huang YuanGui,
Fang Du,
Le WeiDong
Publication year - 2004
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.20315
Subject(s) - dopaminergic , lipopolysaccharide , inflammation , microglia , gallate , chemistry , epigallocatechin gallate , pharmacology , dopamine , medicine , neuroscience , immunology , biology , biochemistry , polyphenol , antioxidant
Microglial activation is believed to play a pivotal role in the selective neuronal injury associated with several neurodegenerative disorders, including Parkinson's disease (PD) and Alzheimer's disease. We provide evidence that (−)‐epigallocatechin gallate (EGCG), a major monomer of green tea polyphenols, potently inhibits lipopolysaccharide (LPS)‐activated microglial secretion of nitric oxide (NO) and tumor necrosis factor‐α (TNF‐α) through the down‐regulation of inducible NO synthase and TNF‐α expression. In addition, EGCG exerted significant protection against microglial activation‐induced neuronal injury both in the human dopaminergic cell line SH‐SY5Y and in primary rat mesencephalic cultures. Our study demonstrates that EGCG is a potent inhibitor of microglial activation and thus is a useful candidate for a therapeutic approach to alleviating microglia‐mediated dopaminergic neuronal injury in PD. © 2004 Wiley‐Liss, Inc.